Contact

Metabolic Models

Metabolic diseases represent a group of disorders that share a common feature which is disruptions in normal metabolic pathways.

Sygnature Discovery scientists have been at the forefront of drug discovery in the metabolic area for almost 20 years. From the discovery and registration of Sibutramine to Empagliflozin, our scientists are uniquely positioned to advance drug development for the treatment of metabolic diseases.

Our Comprehensive Metabolic Disease Models

Understanding the underlying mechanisms of metabolic diseases is critical for developing effective treatments and preventative strategies.

Sygnature Discovery provides integrated offerings from target identification, through molecule design and characterisation to in vitro and in vivo metabolic model modelling.

Our in vivo metabolic models help researchers study the progression of diseases, their underlying pathophysiology, and the response to diverse interventions in a controlled setting. We offer a wide range of metabolic disease models, ranging from genetically modified models to those induced chemically or through dietary manipulation.

In vivo models – therapeutic indications:

Therapeutic Indication Models
Obesity DIO mouse and rat model, Zucker rat modelob/ob mouse model
Insulin resistance Glucocorticoid-induced insulin resistance rat model, DIO mouse and rat model, ob/ob mouse model
Diabetes STZ/HFD mouse and rat model,db/db mouse model, ZDF rat model, ZSF-1 rat model
Kidney Disease STZ/HFD mouse and rat model, ZSF-1 rat model, adriamycin mouse model,anti-GBM mouse and rat model, LPS rat and mouse model
Neuropathy STZ/HFD mouse and rat model,db/db mouse model, ZDF rat model, ZSF-1 rat model
Fatty Liver Disease NASH Choline deficient (CD) mouse model, H-FFC mouse model, H-FFC ob/ob mouse model, H-FFC CCl4 mouse model
Cardiovascular Disease ZSF-1 rat model, adriamycin mouse model

 

Metabolic Diseases Diagram, Main Characteristics, Sygnature Discovery

Key strengths of Metabolic Models:

  • Closely mimic human disease conditions
  • Offer controlled environment
  • Allow investigation of multiple organs and systems
  • Allow mechanistic study
  • Enable synchronised PD and PK

State-of-the-art facilities and cutting-edge technology provide us with the ability to identify and optimise compounds with superior efficacy and safety profiles. Sygnature Discovery’s collaborative approach allows us to work closely with our customers to deliver tailored solutions that meet their specific drug discovery needs.

Our Metabolic Diseases Services

Sygnature Discovery’s in vivo metabolic offering involves using validated animal models to screen and identify novel therapeutic targets and drug candidates for metabolic disorders. We couple our robust in vivo models with metabolic profiling and services including molecular, biochemical and histological marker characterisation as well as a range of ex vivo platforms.

Metabolic profiling:

Blood and plasma biochemistry

  • Plasma ALT, AST, glucose, insulin, C-peptide, adiponectin, leptin, triglycerides, cholesterol, NEFA, bile acids, hyaluronic acid, ketone bodies
  • TIMP-1 and PIIINP
  • HbA1c, urea
  • Urinary glucose, NGAL, MCP-1, protein
  • Cytokines, chemokines

Tissue analysis

  • qPCR such as proinflammatory, profibrotic and diseases specific panels
  • MSD/ELISA such as proinflammatory and disease-specific panels
  • Liver parameters such as triglyceride, cholesterol, NEFA, collagen
  • Pancreatic insulin content
  • Kidney and heart parameters such as triglyceride, collagen, cytokines
  • Fat parameters such as triglyceride

Histology

  • Morphology such as PAS, H&E
  • Inflammation such as F4/80, CD45
  • Fibrosis such as PS, MT

Ex vivo techniques

  • Precision-cut kidney slices
  • Ex vivo binding

Data pack and report

We can provide a fully audited data pack and a written report to regulatory standards if required.

Latest News

View All

Sygnature Discovery Receives EcoVadis Award For Sustainable…

Sygnature Discovery goes for global industry recognition…

First patients dosed in Phase 1a clinical…

Sygnature Discovery Appoints Industry Leaders To Board…